932 related articles for article (PubMed ID: 26432046)
1. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
[TBL] [Abstract][Full Text] [Related]
2. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
[TBL] [Abstract][Full Text] [Related]
3. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Sasaki K; Jabbour EJ; Ravandi F; Short NJ; Thomas DA; Garcia-Manero G; Daver NG; Kadia TM; Konopleva MY; Jain N; Issa GC; Jeanis V; Moore HG; Garris RS; Pemmaraju N; Cortes JE; O'Brien SM; Kantarjian HM
Cancer; 2016 Dec; 122(23):3650-3656. PubMed ID: 27479888
[TBL] [Abstract][Full Text] [Related]
4. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
[TBL] [Abstract][Full Text] [Related]
5. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E; Short NJ; Jain N; Huang X; Montalban-Bravo G; Banerjee P; Rezvani K; Jiang X; Kim KH; Kanagal-Shamanna R; Khoury JD; Patel K; Kadia TM; Daver N; Chien K; Alvarado Y; Garcia-Manero G; Issa GC; Haddad FG; Kwari M; Thankachan J; Delumpa R; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
Lancet Haematol; 2023 Jan; 10(1):e24-e34. PubMed ID: 36402146
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
7. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Kantarjian H; Short NJ; Jain N; Sasaki K; Huang X; Haddad FG; Khouri I; DiNardo CD; Pemmaraju N; Wierda W; Garcia-Manero G; Kebriaei P; Garris R; Loghavi S; Jorgensen J; Kwari M; O'Brien S; Ravandi F; Jabbour E
Am J Hematol; 2023 Mar; 98(3):493-501. PubMed ID: 36600670
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
9. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
Kantarjian H; Ravandi F; Short NJ; Huang X; Jain N; Sasaki K; Daver N; Pemmaraju N; Khoury JD; Jorgensen J; Alvarado Y; Konopleva M; Garcia-Manero G; Kadia T; Yilmaz M; Bortakhur G; Burger J; Kornblau S; Wierda W; DiNardo C; Ferrajoli A; Jacob J; Garris R; O'Brien S; Jabbour E
Lancet Oncol; 2018 Feb; 19(2):240-248. PubMed ID: 29352703
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Cortes JE; Kantarjian H; Shah NP; Bixby D; Mauro MJ; Flinn I; O'Hare T; Hu S; Narasimhan NI; Rivera VM; Clackson T; Turner CD; Haluska FG; Druker BJ; Deininger MW; Talpaz M
N Engl J Med; 2012 Nov; 367(22):2075-88. PubMed ID: 23190221
[TBL] [Abstract][Full Text] [Related]
12. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Jabbour E; Short NJ; Jain N; Thompson PA; Kadia TM; Ferrajoli A; Huang X; Yilmaz M; Alvarado Y; Patel KP; Garcia-Manero G; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
Lancet Haematol; 2022 Dec; 9(12):e878-e885. PubMed ID: 36279879
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Copland M; Slade D; McIlroy G; Horne G; Byrne JL; Rothwell K; Brock K; De Lavallade H; Craddock C; Clark RE; Smith ML; Fletcher R; Bishop R; Milojkovic D; Yap C
Lancet Haematol; 2022 Feb; 9(2):e121-e132. PubMed ID: 34906334
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
[TBL] [Abstract][Full Text] [Related]
17. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Ravandi F; O'Brien S; Thomas D; Faderl S; Jones D; Garris R; Dara S; Jorgensen J; Kebriaei P; Champlin R; Borthakur G; Burger J; Ferrajoli A; Garcia-Manero G; Wierda W; Cortes J; Kantarjian H
Blood; 2010 Sep; 116(12):2070-7. PubMed ID: 20466853
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Othman T; Moskoff BN; Ho G; Tenold ME; Azenkot T; Krackeler ML; Fisch SC; Potter LA; Kaesberg PR; Welborn JL; Wun T; Esteghamat NS; Hoeg RT; Rosenberg AS; Abedi M; Tuscano JM; Jonas BA
Leuk Res; 2022 Aug; 119():106885. PubMed ID: 35738024
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
Morita K; Kantarjian HM; Sasaki K; Issa GC; Jain N; Konopleva M; Short NJ; Takahashi K; DiNardo CD; Kadia TM; Garcia-Manero G; Daver N; Montalban Bravo G; Cortes JE; Ravandi F; Jabbour E
Cancer; 2021 Aug; 127(15):2641-2647. PubMed ID: 33823073
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre P; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DiPersio J; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Wong S; Lustgarten S; Rivera VM; Clackson T; Turner CD; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes T; Goldman JM; Shah NP; Kantarjian H;
N Engl J Med; 2013 Nov; 369(19):1783-96. PubMed ID: 24180494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
